May 10, 2018 / 11:40 AM / in 4 months

BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48

May 10 (Reuters) - Syros Pharmaceuticals Inc:

* SYROS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES

* Q1 REVENUE VIEW $4 MILLION — THOMSON REUTERS I/B/E/S

* Q1 EARNINGS PER SHARE VIEW $-0.39 — THOMSON REUTERS I/B/E/S

* SYROS PHARMACEUTICALS - PLAN TO OPEN SINGLE-AGENT, COMBINATION EXPANSION COHORTS IN PHASE 1 TRIAL OF SY-1365 IN MID-2018

* SYROS - EXPECT TO REPORT INITIAL DATA FROM COMBINATION ARMS OF PHASE 2 TRIAL OF SY-1425, DOSE ESCALATION PORTION OF PHASE 1 TRIAL OF SY-1365 IN Q4 2018

* SYROS PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $121.7 MILLION, VERSUS $72.0 MILLION ON DEC 31, 2017

* SYROS - BELIEVES EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TO BE SUFFICIENT TO ENABLE CO TO FUND PLANNED OPERATING EXPENSES INTO 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below